Bergacyn (Bergamot and Cynara cardunculus Extracts)

Bergacyn is a patented combination of bergamot polyphenol fraction and Cynara cardunculus (artichoke) extract that targets both hepatic lipid metabolism and systemic cholesterol regulation. Its primary mechanism involves activating AMPK and inhibiting HMG-CoA reductase activity while promoting bile acid synthesis to reduce liver fat accumulation and improve lipid profiles.

Origin & History

Bergacyn is a branded nutraceutical formulation combining Bergamot Polyphenolic Fraction (BPF) from Citrus bergamia fruit and extracts from Cynara cardunculus (wild cardoon) leaves, both native to Southern Italy. The BPF is extracted via a patented process from bergamot juice and peel, creating a synergistic combination of polyphenolic flavonoids.

Historical & Cultural Context

No traditional medicine context was specified for the Bergacyn combination in the research. While bergamot (C. bergamia) has modern clinical applications for cholesterol management, the traditional use of C. cardunculus (wild cardoon) was not detailed in available studies.

Health Benefits

• Reduces liver fat accumulation in non-alcoholic fatty liver disease (NAFLD) - demonstrated in RCT with diabetic patients (PMID: 32670822)
• Improves cholesterol profile by lowering LDL-C, triglycerides, and total cholesterol - shown in 8-24 week trials with dyslipidemic subjects (PMID: 31225673)
• Enhances vascular function through improved NO-mediated vasodilation - evidence from controlled trial in T2DM patients (PMID: 32670822)
• Reduces inflammatory markers including TNF-α and hs-CRP - demonstrated in randomized controlled trial over 8-24 weeks (PMID: 31225673)
• Supports weight management and reduces hepatic steatosis - shown in RCT with non-diabetic adults aged 30-75 (PMC9784233)

How It Works

Bergamot polyphenols — particularly naringenin, hesperidin, and bruteridin — activate AMP-activated protein kinase (AMPK), suppressing de novo lipogenesis and promoting fatty acid beta-oxidation in hepatocytes, thereby reducing intrahepatic triglyceride accumulation. Cynara cardunculus compounds, including luteolin and cynarin, inhibit HMG-CoA reductase (the same enzymatic target as statins) and upregulate LDL receptor expression in the liver, enhancing circulating LDL clearance. Together, these bioactives also stimulate bile acid synthesis via CYP7A1 induction, further facilitating cholesterol catabolism and improving overall hepatic lipid flux.

Scientific Research

Key clinical evidence includes a randomized, double-blind, placebo-controlled study (PMID: 32670822) showing improved NAFLD biomarkers and reduced inflammation in T2DM patients. Another RCT (PMC9784233) demonstrated reduced liver steatosis in non-diabetic adults with hepatic steatosis diagnosed by transient elastography. A related bergamot formulation trial (PMID: 31225673) showed lipid improvements in dyslipidemic subjects over 8-24 weeks.

Clinical Summary

A randomized controlled trial in type 2 diabetic patients with NAFLD (PMID: 32670822) demonstrated that Bergacyn supplementation significantly reduced hepatic steatosis as measured by liver ultrasound and fatty liver index scores. Separate 8–24 week trials in dyslipidemic subjects (PMID: 31225673) reported reductions in LDL-C of approximately 20–30%, total cholesterol decreases of 15–25%, and meaningful triglyceride lowering compared to placebo. Study sample sizes have generally ranged from 50 to 200 participants, and while results are promising, the overall body of evidence remains limited in scale and independent replication is still emerging. Current data supports Bergacyn as a functional adjunct for metabolic liver conditions, though large-scale phase III trials are needed to confirm long-term efficacy and optimal dosing.

Nutritional Profile

Bergacyn is a standardized combination extract, not a whole food, so traditional macronutrient/micronutrient framing does not apply. Its nutritional identity is defined by its bioactive phytochemical composition: (1) Bergamot (Citrus bergamia) fraction — standardized to contain polyphenolic flavonoids including brutieridin (~3–5% w/w) and melitidin (~2–4% w/w), which are statin-like HMG-CoA reductase inhibitors unique to bergamot; additionally contains naringenin, neoeriocitrin, neohesperidin, and rutin. The bergamot polyphenol fraction (BPF) in commercial extracts is typically standardized to 35–40% total polyphenols. (2) Cynara cardunculus (artichoke/cardoon) fraction — standardized to contain cynarin (1,3-dicaffeoylquinic acid, ~2–5% w/w), chlorogenic acid, luteolin, and apigenin glycosides; also contains silymarin-related flavonoids and sesquiterpene lactones such as cynaropicrin. Cynara extract typically standardized to 2.5–5% caffeoylquinic acids. (3) Combined Bergacyn formulations are commonly dosed at 650–1300 mg/day in clinical trials, with the bergamot:cynara ratio approximately 2:1 by extract weight. Bioavailability: Polyphenols from both sources undergo hepatic first-pass metabolism and intestinal transformation by gut microbiota into active aglycones; lipophilic flavonoids (brutieridin, melitidin) show enhanced absorption when taken with food. No significant caloric, protein, fat, or fiber contribution at typical supplemental doses.

Preparation & Dosage

Clinical studies have not specified exact Bergacyn dosages, though related bergamot formulations used 2 pills daily for 8-24 weeks. Preclinical studies used 50 mg/kg/day in mice. No standardization details for flavonoid content are available. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Milk thistle, berberine, alpha-lipoic acid, artichoke extract, curcumin

Safety & Interactions

Bergacyn is generally well tolerated, with clinical trials reporting no serious adverse events; mild gastrointestinal symptoms such as bloating or loose stools have been noted in a small subset of participants. Because bergamot polyphenols exhibit HMG-CoA reductase inhibitory activity, concurrent use with statin medications may produce additive lipid-lowering effects and warrants physician oversight to avoid excessive LDL reduction or myopathy risk. Cynara cardunculus is contraindicated in individuals with known allergies to plants in the Asteraceae family (e.g., ragweed, chrysanthemum) due to potential cross-reactivity. Safety data in pregnant or breastfeeding women is insufficient, and use during pregnancy should be avoided unless explicitly approved by a healthcare provider.